Start small, think big: Gen­mab racks up a bis­pe­cif­ic de­vel­op­ment deal with HIV spe­cial­ist Gilead

Gen­mab is on a roll. The biotech has inked an­oth­er high-pro­file col­lab­o­ra­tion deal — this time with Gilead — that will put its bis­pe­cif­ic an­ti­body tech to work on HIV ther­a­pies.

The deal starts small, with Gilead hand­ing over a $5 mil­lion up­front and fol­low­ing it up with $277 mil­lion-plus in po­ten­tial mile­stones, de­pend­ing on how far Gen­mab can get. The Dan­ish com­pa­ny is us­ing its Duo­Body plat­form on the deal, which boasts an abil­i­ty to bind to dif­fer­ent tar­gets with­out los­ing the ther­a­peu­tic punch ex­pect­ed from a sin­gle an­ti­body.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.